Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.51 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732158 | 0.90 | NR4A2 (0.75) | PTGS2PTGS1NR4A2NR4A1NR4A3 | |
| SCHEMBL7500434 | 0.90 | NR4A2 (0.75) | PTGS2PTGS1NR4A2NR4A1NR4A3 | |
| SCHEMBL7868750 | 0.89 | PTGS2 (0.67) | PTGS2PTGS1NR4A2NR4A1NR4A3 | |
| SCHEMBL5732857 | 0.88 | RXRA (0.62) | PTGS2PTGS1NR4A2NR4A1NR4A3 | |
| SCHEMBL5732397 | 0.88 | RXRA (0.62) | PTGS2PTGS1NR4A2NR4A1NR4A3 | |
| SCHEMBL7503465 | 0.88 | PTGS2 (0.62) | PTGS2PTGS1NR4A2NR4A1NR4A3 | |
| SCHEMBL6025799 | 0.86 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL5732600 | 0.86 | RXRA (0.63) | PTGS2PTGS1NR4A2NR4A1NR4A3 | |
| SCHEMBL7500076 | 0.85 | PTGS2 (0.61) | PTGS2PTGS1NR4A2 | |
| SCHEMBL7511025 | 0.84 | PTGS2 (0.65) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479385-B1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | SEARLE LLC (US) | 2008-07-02 | — | — | EP | claimed |
| US-20060251689-A1 | Treatment or prevention of pruritus | ASTION DEVELOPMENT A/S | 2006-11-09 | — | — | US | claimed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | claimed |
| WO-2006102899-A2 | OXAPROZIN OR CLOSELY RELATED COMPOUND FOR THE TREATMENT AND PREVENTION OF | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102900-A1 | DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ASTION DEVELOPMENT A/S | 2006-10-05 | — | — | US | claimed |
| EP-1707200-A1 | Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707201-A1 | Oxaprozin or a closely related compound for the treatment of eczema | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707199-A1 | Oxaprozin or closely related compound for the treatment and prevention of pruritus | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-0932402-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | G.D. SEARLE & CO. (US) | 1999-08-04 | — | — | EP | claimed |
| WO-1998016227-A9 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | — | 1998-07-30 | — | — | WO | claimed |
| WO-1998022101-A2 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS | G.D. SEARLE & CO. (US) | 1998-05-28 | — | — | WO | claimed |
| EP-0843549-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-05-27 | — | — | EP | claimed |
| WO-1998016227-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | G.D. SEARLE & CO. (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0833664-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4? RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| EP-0699192-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-06 | — | — | EP | claimed |
| WO-1994027980-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1994-12-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229347-A1 | Treatment of eczemas | ZAP70, SYK, LCK | PTGS2 792/4885PTGS1 745/4885NR4A2 1164/4885 |
| US-20060251689-A1 | Treatment or prevention of pruritus | ITCH, TSLP, HRH4 | PTGS2 169/4885PTGS1 131/4885NR4A2 1009/4885 |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ZAP70, SYK, LCK | PTGS2 1589/4885PTGS1 1534/4885NR4A2 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.